IBSD Resource Page Banner

Resource Center

A Helpful Suite of Clinical Resources for Your Practice

Want to learn more about best practices in diagnosis and management of irritable bowel syndrome with diarrhea (IBS-D)? Access peer-guided videos, clinical tools, and comprehensive guides to help your patients throughout their journey.

Diagnosis of IBS-D

Grey play button with square border.Video

11 mins

My Approach: Making a Positive IBS-D Diagnosis

A Practical Overview Featuring Jaime Ackerman, PA-C

Watch your peer demonstrate how she uses a guideline-based approach and clinical criteria to make a positive diagnosis of IBS-D.

 

Informational guide for diagnosing IBS-D, including clinical criteria and suggestions for conversation starters you can use with your patients.

Understanding IBS-D

Grey play button with square border.Video

19 mins

Potential Causes of Your Adult Patients’ IBS-D Symptoms

Hosted by Christina J. Hanson, FNP
Featuring Amy Kassebaum, PA-C, MMS, RD

Learn about factors that are thought to contribute to IBS-D symptoms.

View TranscriptRed carrot symbol pointing right.

White download button on
red background.Download Podcast Audio

 
View Transcript
Don’t have time to watch the full episode above? View clips below.

Grey play button with square border.Video

3 mins

Bacterial Imbalance and IBS-D Symptoms

 

Grey play button with square border.Video

6 mins

How XIFAXAN® (rifaximin) Is Thought to Work

 

Grey play button with square border.Video

3 mins

Expert Discussion: The Role of Dysbiosis in the Pathophysiology of IBS-D

Watch Dr. Chang explain how microbial imbalances in the gut are thought to be linked to IBS-D symptoms.

 

Grey play button with square border.Video

13 mins

Expert Discussion: Role Gut Microbiota May Play in the Etiology of IBS-D

Discussion from experts Mark Pimentel, MD, and Darren Brenner, MD, on the role of gut microbiota in human health and how dysbiosis may lead to symptoms of IBS-D.

 

Grey play button with square border.Video

6 mins

Expert Discussion: Pathophysiology of IBS-D and Mechanism of Action of XIFAXAN

Discussion from expert Mark Pimentel, MD, on the complex pathophysiology of IBS-D and the mechanism of action of XIFAXAN.

 

Patient Case Studies

Consult these peer-guided patient case videos to help identify adult patients for whom XIFAXAN may be an appropriate therapy.

Grey play button with square border.Video

8 mins

Recognizing the Symptoms of IBS-D

Featuring Kimberly Kearns, MS, APRN, ANP-BC

Follow along on the journey of Greg, a 29-year-old male who was referred to a gastroenterology specialist for frequent diarrhea accompanied by abdominal pain.

White download button on red background.
Download Case Overview

 

Grey play button with square border.Video

8 mins

The Cycle of IBS-D Symptoms

Featuring Amy L. Stewart, CRNP

Follow along on the journey of Maria, a 38-year-old female who presented to her primary care provider with frequent abdominal pain associated with diarrhea during the past 4 months.

White download button on red background.Download Case Overview

 

Download and share this handout with your peers to direct them to IBS-D and overt HE patient case studies presented by practicing APPs.

Clinical Practice

Watch fellow clinicians discuss clinical insights in the management of adult patients with IBS-D.

Grey play button with square border.Video

10 mins

My Approach: Expediting IBS-D Management

A Practical Overview Featuring Tedra Gray, NP

See how your peer creates an open dialogue with a hypothetical patient, and gain insights into managing multiple symptoms of IBS-D. Discover why Tedra chooses XIFAXAN for her adult patients with IBS-D.

 

Grey play button with square border.Video

23 mins

Managing Your Adult Patients’ IBS-D Symptoms

Hosted by Christina J. Hanson, FNP
Featuring Kim Orleck, PA-C

Recognize the recurring symptoms of IBS-D, and learn how treatment with XIFAXAN may help provide relief for your appropriate patients.1,2

View TranscriptRed carrot symbol pointing right.

White download button on red background.Download Podcast Audio

 
View Transcript
Don’t have time to watch the full episode above? View clips below.

Grey play button with square border.Video

3 mins

Connecting With IBS-D Patients and Defining Success

 

Grey play button with square border.Video

8 mins

Managing IBS-D With XIFAXAN® (rifaximin)

 

Grey play button with square border.Video

10 mins

Expert Discussion: Managing IBS-D Symptoms

Featuring Mark Pimentel, MD, Darren Brenner, MD, and Joscelyn Greaves, NP

Learn about nonpharmacologic and pharmacologic interventions to help manage IBS-D and the challenges faced by patients living with IBS-D.

 

Grey play button with square border.Video

16 mins

Expert Discussion: Treating IBS-D as a Multi-Symptom Condition

Watch Dr. Brenner explain the importance of recognizing the multiple symptoms of IBS-D and how XIFAXAN may help address these symptoms.

 

Diagnostic Recommendations for IBS-D and Treatment Using Rifaximin: Real-World Perspectives

Features diagnostic and treatment recommendations for IBS-D and real-world perspectives from Mark Pimentel, MD, and Amy Kassebaum-Ladewski, PA-C, RD, MMS.

Grey play button with square border.Video

4 mins

Expert Discussion: ACG Recommendation for XIFAXAN

Watch Dr. Cash discuss the inclusion of XIFAXAN as a treatment for adults with IBS-D in the American College of Gastroenterology’s 2020 Clinical Guideline on Managing IBS-D.

 

Grey play button with square border.Video

16 mins

Expert Discussion: Treating IBS-DWith XIFAXAN

Featuring Mark Pimentel, MD, Darren Brenner, MD, and Joscelyn Greaves, NP

Learn how XIFAXAN may be able to help your adult patients with IBS-D and how to appropriately set expectations prior to treatment.

 

Grey play button with square border.Video

7 mins

Expert Review: Efficacy and Safety of XIFAXAN

Dr. Brenner speaks about the efficacy and safety of XIFAXAN shown in clinical trials. Review key data supporting the use of XIFAXAN for your adult patients with IBS-D.

 

For Your Patients

Encourages patients to have a discussion with you about the symptoms they experience and if treatment with XIFAXAN may be an option. Have your patients complete the quick discussion questions to aid in symptom-based diagnosis.

Informational brochure for patients that provides an overview of IBS-D and treatment with XIFAXAN, including how XIFAXAN works, how to take XIFAXAN, efficacy, safety, and most common side effects. Provide this brochure to patients to help them understand treatment with XIFAXAN.

XIFAXAN® (rifaximin) $0 copay savings card for eligible commercially insured patients.
External link icon indicating navigation to an outside webpage.Link

XIFAXAN Savings Card

Most eligible* patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.

Highlights XIFAXAN efficacy and safety data, dosing, and the steps to complete a prior authorization. Share this guide with colleagues who may less frequently treat adult patients with IBS-D.

Review the recommended XIFXAN dosing for adults with IBS-D.

Core information on XIFAXAN for the treatment of IBS-D in adults. Provides an overview of symptom-based diagnosis of IBS-D, pathophysiology, and efficacy and safety data for XIFAXAN, as well as information on insurance coverage.

Grey play button with square border.Video

7 mins

Ensure XIFAXAN Prescriptions Are Written Correctly

Watch as Clinical Pharmacy Specialist Ralph Riello, PharmD, discusses best practices to help with XIFAXAN prior authorization.

 

Step-by-step guide for completing prior authorization (PA) requirements for patients prescribed XIFAXAN, including common reasons for PA denials and guidance for Letters of Medical Necessity when needed. Download for guidance on PA requests, as well as information on electronic submissions with CoverMyMeds.

A tier exemption request to reduce the cost-share of a medication. Follows submission of a prior authorization or utilization management request.

A standard form for a patient-specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

*Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.

See More

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • ​​XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
See Less

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • ​​XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:

    HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)

    IBS-D (≥2%): Nausea (3%), ALT increased (2%)

  • ​​INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References: 1. XIFAXAN (rifaximin) tablets [package insert]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.

XIFI.0136.USA.24V3.0